Selection between sunitinib and ripretinib using mutation analysis for gastrointestinal stromal tumor patients progressing on imatinib

被引：0
|
作者：
Joensuu, Heikki [1 ,2 ]
机构：
[1] Helsinki Univ Hosp, Dept Oncol, POB 180,Haartmaninkatu 4, Helsinki 00029, Finland
[2] Univ Helsinki, POB 180,Haartmaninkatu 4, Helsinki 00029, Finland
来源：
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY | 2024年 / 9卷
关键词：
Gastrointestinal stromal tumor (GIST); imatinib; sunitinib; ripretinib; PHASE-II TRIAL; KINASE INHIBITOR; EFFICACY; KIT; RESISTANCE; SCHEDULE; MESYLATE; SAFETY;
D O I：
10.21037/tgh-24-32
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib
    Nemunaitis, John
    Bauer, Sebastian
    Blay, Jean-Yves
    Choucair, Khalil
    Gelderblom, Hans
    George, Suzanne
    Schoffski, Patrick
    von Mehren, Margaret
    Zalcberg, John
    Achour, Haroun
    Ruiz-Soto, Rodrigo
    Heinrich, Michael C.
    FUTURE ONCOLOGY, 2020, 16 (01) : 4251 - 4264
  • [2] Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
    Sawaki, Akira
    Kanda, Tatsuo
    Komatsu, Yoshito
    Nishida, Toshirou
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2014, 2014
  • [3] Clinical Efficacy and Safety of Sunitinib After Imatinib Failure in Japanese Patients with Gastrointestinal Stromal Tumor
    Matsumoto, Kazuya
    Sawaki, Akira
    Mizuno, Nobumasa
    Hara, Kazuo
    Hijioka, Susumu
    Niwa, Yasumasa
    Tajika, Masahiro
    Kawai, Hiroki
    Kondo, Shinya
    Yamao, Kenji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (01) : 57 - 62
  • [4] Genotyping guided ripretinib directly after the progression of first-line imatinib therapy in advanced gastrointestinal stromal tumor: a case report
    Huang, Shaoqing
    Guo, Xiaodan
    Xia, Yanzhe
    Ding, Li
    Zhai, Ertao
    Chen, Sile
    He, Yulong
    Cai, Shirong
    Zhang, Xinhua
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (02)
  • [5] Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives
    Mulet-Margalef, Nuria
    Garcia-del-Muro, Xavier
    ONCOTARGETS AND THERAPY, 2016, 9 : 7573 - 7582
  • [6] Sunitinib in patients with imatinib-resistant gastrointestinal stromal tumor: A single center experience
    Sahu, A.
    Godbole, S.
    Jain, P.
    Ghosh, J.
    Shrikhande, S.
    Ramadwar, M.
    Goyal, M.
    Gulia, S.
    Bajpai, J.
    Kembhavi, Y.
    Gupta, S.
    INDIAN JOURNAL OF CANCER, 2015, 52 (03) : 320 - U91
  • [7] Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial
    Heinrich, Michael C.
    Jones, Robin L.
    George, Suzanne
    Gelderblom, Hans
    Schoeffski, Patrick
    von Mehren, Margaret
    Zalcberg, John R.
    Kang, Yoon-Koo
    Razak, Albiruni Abdul
    Trent, Jonathan
    Attia, Steven
    Le Cesne, Axel
    Siontis, Brittany L.
    Goldstein, David
    Boye, Kjetil
    Sanchez, Cesar
    Steeghs, Neeltje
    Rutkowski, Piotr
    Druta, Mihaela
    Serrano, Cesar
    Somaiah, Neeta
    Chi, Ping
    Reichmann, William
    Sprott, Kam
    Achour, Haroun
    Sherman, Matthew L.
    Ruiz-Soto, Rodrigo
    Blay, Jean-Yves
    Bauer, Sebastian
    NATURE MEDICINE, 2024, 30 (02) : 498 - 506
  • [8] Relationship between efficacy of sunitinib and KIT mutation of patients with advanced gastrointestinal stromal tumors after failure of imatinib A systematic review
    Xie, Fuming
    Xiao, Weidong
    Jiang, Yahui
    Xia, Xiao
    Wang, Yaxu
    MEDICINE, 2019, 98 (19)
  • [9] Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
    Bauer, Sebastian
    Jones, Robin L.
    Blay, Jean-Yves
    Gelderblom, Hans
    George, Suzanne
    Schoeffski, Patrick
    von Mehren, Margaret
    Zalcberg, John R.
    Kang, Yoon-Koo
    Razak, Albiruni Abdul
    Trent, Jonathan
    Attia, Steven
    Le Cesne, Axel
    Su, Ying
    Meade, Julie
    Wang, Tao
    Sherman, Matthew L.
    Ruiz-Soto, Rodrigo
    Heinrich, Michael C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (34) : 3918 - +
  • [10] Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial
    Symcox, Marina
    Jones, Robin L.
    FUTURE ONCOLOGY, 2023, 19 (36) : 2383 - 2393
12345